Citation Impact
Citing Papers
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
2009
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
2011 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Phase I trial of temozolomide using an extended continuous oral schedule.
1998
Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase
1995
An Overview of Cyclophosphamide and Ifosfamide Pharmacology
1997
Immunotherapy of cancer in 2012
2012
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
2003
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Inflammation and cancer
2002 StandoutNature
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
A view on drug resistance in cancer
2019 StandoutNature
WAF1, a potential mediator of p53 tumor suppression
1993 Standout
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
1990 StandoutNature
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Cytogenetics of non‐small cell lung cancer: Analysis of consistent non‐random abnormalities
1990
Molecular Analysis of the Short Arm of Chromosome 3 in Small-Cell and Non-Small-Cell Carcinoma of the Lung
1987
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
2002
Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma.
1991
Survival of human glioma cells treated with various combination of temozolomide and X-rays
2000
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells
1989 StandoutNature
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
1991 StandoutNature
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
2006
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
1997
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Angiogenesis in life, disease and medicine
2005 StandoutNature
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
2015
A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
1994 StandoutScience
Chemotherapy for Malignant Pleural Mesothelioma
2003
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
1987
Cancer immunotherapy comes of age
2011 StandoutNature
Management of Metastatic Melanoma 2005
2006
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
1992 Standout
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis
1990 Nature
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
TRPA1 Mediates the Inflammatory Actions of Environmental Irritants and Proalgesic Agents
2006 StandoutNobel
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Role of bacillus Calmette–Guérin in the treatment of advanced melanoma
2011
Angiogenesis as a therapeutic target
2005 StandoutNature
Advances in Malignant Mesothelioma
2005 Standout
Inactivation of p16INK4a expression in malignant mesothelioma by methylation
2002
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
2006
Inhibition of the Met Receptor in Mesothelioma
2005
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
2001 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
2003
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents
2003
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
1999
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
The intriguing role of polymorphonuclear neutrophils in antitumor reactions
2001
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
1989 StandoutScience
Cancer Genome Landscapes
2013 StandoutScience
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
2001 Standout
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
2009
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
2005
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
2002
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016
High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6
2001 StandoutNobel
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma
2004
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
1999 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis
1998
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
1992 StandoutScience
Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors.
1996
Works of N. Thatcher being referenced
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells
1993
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody
1990
Escalating drug delivery in cancer chemotherapy: A review of concepts and practice —Part 2
1993
Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy
1994
Lack of correlation between peripheral blood lymphokine‐activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2
1989
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients
1988
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma
2000
Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma
1992
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
2016
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
1998
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide
1994
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
1994
Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
1998
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
1995
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
1998
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
2000
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
2006
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
2010
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib
2004
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours
1986
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.
1991
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
2000
Genetic predisposition to human lung cancer
1986
Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
2008
Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients
1987
Basic principles in the use of adjuvant therapy.
1990
Alternate splicing produces a novel cyclin D1 transcript.
1995
Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma
2003
Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma
2003
Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
2015
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
1991